Sciele Pharma Announces That the FDA Has Issued an Approvable Letter for the Head Lice Treatment Chiropractic Economics 18 years ago Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that the U.S. Food & Drug Administration (FDA) Related Posts How payer code-edits impact the chiropractic billing process Colorado to have standardized insurance cards ACA House of Delegates: Chiropractic qualified to fill gaps in primary healthcare Chiropractors exempt from massage establishment regulation Discover the many benefits of regenerative medicine